Catalent, Inc.CTLT was a big mover last session, as the company saw its shares rise almost 14% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. The stock picked up sharply from the near-flat trend of $33.75 to $35.68 in the past one-month time frame.
The move came after the company reported solid fourth-quarter fiscal 2017 results. Also, management revealed that it has inked a long-term supply agreement to make the next generation of Pfizer's over-the-counter pain relief, along with the launch of Advil Liqui-Gels Minis.
The company has not seen any estimate revisions over the past one month, while the Zacks Consensus Estimate for the current quarter also remained unchanged. The recent price action is encouraging though, so make sure to keep a close watch on this firm in the near future.
Catalent currently carries a Zacks Rank #2 (Buy) while its Earnings ESP is 0.00%.
Catalent, Inc. Price
Another player in the Medical - Drugs industry, which looks attractive at current levels is Akebia Therapeutics, Inc. AKBA , which has the same Zacks Rank as Catalent. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .
4 Surprising Tech Stocks to Keep an Eye On
Tech stocks have been a major force behind the market's record highs, but picking the best ones to buy can be tough. There's a simple way to invest in the success of the entire sector. Zacks has just released a Special Report revealing one thing tech companies literally cannot function without. More importantly, it reveals 4 top stocks set to skyrocket on increasing demand for these devices. I encourage you to get the report now - before the next wave of innovations really takes off.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.